Cardiology and CTVS

Prasugrel Monotherapy Safe, Effective After PCI In Patients With Stable CAD, Finds Study

• byDoctor News Daily Team
• 18 February, 2025
• 0 Comments
• 0 Mins

Aspirin-free prasugrel monotherapy following successful everolimus-eluting stent implantation has demonstrated feasibility and safety without any stent thrombosis in selected low-risk patients with stable CAD, suggests the findings of a recent research from the Journal of the American College of Cardiology.
Patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) are traditionally treated with aspirin and a P2Y12 inhibitor during the first period post-procedure (so-called dual-antiplatelet therapy [DAPT]), followed by withdrawal of the P2Y12 inhibitor and maintenance of aspirin as the single antiplatelet drug thereafter.but recently this has been put to debate among the medical professionals who urge that the best antithrombotic approach after stenting is still an open matter to debate. The adequate duration of DAPT, aswell as the best agent for the subsequent monotherapy phase, have been scrutinized in recent studies . In this regard, a number of recent trials have shown promising results with a scheme comprising short DAPT duration (i.e., 1 to 3 months) followed by the administration of solely a P2Y12 antagonist, instead of aspirin.
Recent studies have suggested that short dual-antiplatelet therapy strategies may provide an adequate balance between ischemic and bleeding risks. However, the complete omission of aspirin immediately after percutaneous coronary intervention (PCI) has not been tested so far.
The aim of this study, a multicenter, single-arm, open-label, first-in-human, proof-of-concept pilot trial, was to evaluate the hypothesis that prasugrel monotherapy following successful everolimus-eluting stent implantation is feasible and safe in patients with stable coronary artery disease (CAD).
A team under Norihiro Kogame,from the Department of Cardiology, Amsterdam University Medical Center, designed the study as a multicenter, single-arm, open-label trial with a stopping rule based on the occurrence of definite stent thrombosis (if >3, trial enrollment would be terminated). Patients undergoing successful everolimus-eluting stent implantation for stable CAD with SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery)scores <23 were included. All participants were on standard dual-antiplatelet therapy at the time of index PCI. Aspirin was discontinued on the day of the index procedure but given prior to the procedure; prasugrel was administered in the catheterization laboratory immediately after the successful procedure, and aspirin-free prasugrel became the therapy regimen from that moment. Patients were treated solely with prasugrel for 3 months. The primary ischemic endpoint was the composite of cardiac death, spontaneous target vessel myocardial infarction, or definite stent thrombosis, and the primary bleeding endpoint was Bleeding Academic Research Consortium types 3 and 5 bleeding up to 3 months.
Data analysis revealed the following facts.
From February 22, 2018, to May 7, 2019, 201 patients were enrolled. All patients underwent PCI for stable CAD.
Overall, 98.5% of patients were adherent to prasugrel at 3-month follow-up. The primary ischemic and bleeding endpoints occurred in 1 patient (0.5%).
No stent thrombosis events occurred.
"Aspirin-free prasugrel monotherapy was feasible and safe following successful DES implantation in a population of selected patients with stable CAD with low anatomic complexity. Our findings may help underpin larger randomized controlled studies to evaluate the aspirin-free strategy compared with traditional DAPT following PCI." Opined the research team.
Primary source: Journal of the American College of Cardiology